Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive inflammatory liver disease with a global prevalence of 5% in the adult population.1 If left undiagnosed and untreated, MASH can progress to advanced liver disease with fibrosis and eventually cirrhosis resulting in an increased risk of hepatic and extrahepatic outcomes, including decompensated cirrhosis, hepatocellular carcinoma, and increased mortality.2 Lifestyle interventions – including diet and exercise targeting weight loss – remain the cornerstone of MASH management.
No takes yet. Share an insight, caveat, or question.
Michel et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: